The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognosis and survival evaluation in treating high-risk BRAF V600 mutation stage III or IV melanoma with dabrafenib plus trametinib therapy: A meta-analysis of 2,660 patients.
 
Arturo Ortiz
No Relationships to Disclose
 
Aldo Ascencio
No Relationships to Disclose
 
Diego Pichardo Rojas
No Relationships to Disclose
 
Nancy Arreola Sevilla
No Relationships to Disclose
 
William Olivos Zegarra
No Relationships to Disclose
 
Eva Valadez Montero
No Relationships to Disclose
 
Alfonso Alvarez Castro
No Relationships to Disclose
 
Leslie Morales Alvarez
No Relationships to Disclose
 
Jose Flores Valdes
No Relationships to Disclose
 
Jaqueline Livier Castillo
No Relationships to Disclose
 
Jorge Cortes
Consulting or Advisory Role - Bio-Path Holdings, Inc; Enliven Therapeutics; Gilead Sciences; Novartis; Pfizer; Rigel; Sun Pharma; Syndax; Takeda; Terns Pharmaceuticals
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Bio-Path Holdings, Inc (Inst); Cyto Agents (Inst); Jazz Pharmaceuticals (Inst); Kuro Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst)
 
Brenda Santellano
No Relationships to Disclose